Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication

  • Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer drug in nine European countries: Germany (the reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain, and The Netherlands. The sanction pertains to the six-month sustained-release formulation of Decapeptyl® and was given through the European decentralized procedure.

    The companies say that the this new formulation will probably be launched first in Germany, The Netherlands, and Spain. The new sustained-release LHRH agonist is indicated for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

    Decapeptyl® is already available in monthly or quarterly sustained-release formulations as well as a daily formulation. The drugs are marketed worldwide for the treatment of advanced prostate cancer, endometriosis, precocious puberty, IVF applications, and uterine fibroids.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »